{
  "abstract": "The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented substantial new data on antibody–drug conjugates (ADCs) in lung cancer, highlighting the ongoing expansion of ADC-based strategies from later-line treatment toward first-line combination regimens. This focused narrative review summarizes and discusses the efficacy and safety findings of ADCs targeting TROP2, HER2, Nectin-4, PD-L1, c-Met, B7-H3, DLL3, SEZ6, and other emerging targets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular attention to emerging ADC plus immune checkpoint inhibitor combinations in the first-line setting. Taken together, these findings highlight an expanding ADC landscape in lung cancer. However, many of the emerging strategies remain supported primarily by preliminary conference-reported or early-phase data and therefore require confirmation in mature peer-reviewed studies and adequately powered randomized clinical trials.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University",
    "Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiaolei Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jiayuan Miao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuxuan Bao"
    },
    {
      "affs": [
        0
      ],
      "name": "Wanli Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xin Yan"
    },
    {
      "affs": [
        1
      ],
      "name": "Mei Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Hongchang Shen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7ss70y02kp7sf.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1943176",
  "fulltext_url": "https://europepmc.org/articles/PMC13683836",
  "id": "7ss70y02kp7sf",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1943176/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7220859953",
  "pdf_url": "https://europepmc.org/articles/PMC13683836?pdf=render",
  "pmcid": "PMC13683836",
  "pmid": "42909136",
  "published": "2026-10-06",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/7ss70y02kp7sf.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1943176",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1943176/full"
    },
    {
      "first_seen": "2026-10-30T12:20:14Z",
      "native_id": "MED:42909136",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42909136"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting",
  "title_text": "Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:14Z",
  "url": "https://research.draconitic.com/paper/7ss70y02kp7sf",
  "venue": "Frontiers in Oncology",
  "versions": []
}